Heavy Menstrual Bleeding: One Woman's Story and What Treatment Involves

• Heavy menstrual bleeding affects roughly 1 in 4–5 women of reproductive age and is a treatable medical condition — not a normal variant to suffer through.
• Untreated HMB is a major driver of iron-deficiency anaemia in Indian women; the full fix means treating both the anaemia and the bleeding that causes it.
• Evaluation is simple and affordable: history, examination, a basic blood panel (haemoglobin, ferritin, thyroid, coagulation, pregnancy test) and a pelvic ultrasound — roughly ₹3,000–5,000 privately, free or minimal at government facilities.
• Treatment is stepped care: first-line mefenamic acid and tranexamic acid, then the levonorgestrel IUS (Mirena), then procedures such as ablation, myomectomy, embolisation or hysterectomy if needed.
• Red flags — soaking a pad hourly for 2+ hours, clots larger than a ₹2 coin, periods over 7 days, night-time changes, fainting or breathlessness — warrant a gynaecology visit without delay.

Priya is 38, a senior project manager at a Bengaluru software company, married with two children aged ten and seven. Her story is a composite drawn from typical FOGSI clinical practice — illustrative of how heavy menstrual bleeding unfolds for many Indian women.

Looking back, Priya thinks the bleeding had been getting heavier for about five years, but the change was gradual enough that she did not recognise it as a problem until it became severe. In her late twenties her periods were already heavy by her friends' standards — she always used heavy-flow pads, often double-padded for the first two days, and managed occasional accidents with dark clothing and back-up supplies. Like many Indian women, she had internalised this as her normal and rarely mentioned it at the few general health visits she had.

The shift accelerated after her second pregnancy at 31. Her periods returned heavier than before. By 35 she was using ultra-thick maternity pads for the first three days of every cycle, changing them every hour on day one and every two hours on days two and three. She planned her work calendar around her periods, taking leave for the heaviest days and avoiding travel and outdoor meetings. She had begun passing large clots — sometimes the size of a small lime — that produced a sense of dread when she felt them coming, and had endured several embarrassing accidents at work and on flights.

In the months before she finally saw a gynaecologist, Priya was waking three or four times a night to change pads on the heaviest days, leaving her exhausted and irritable. She noticed breathlessness climbing the two flights to her office, her hair was thinning, and she felt tired all the time — which she put down to work and family. Her husband had noticed her exhaustion and pallor, but both assumed it reflected a busy life rather than a medical condition.

The breaking point came in March, when Priya nearly fainted at a client meeting. She excused herself, recovered enough to finish the day, and booked a gynaecology appointment the next morning. Her blood tests showed severe iron-deficiency anaemia — a haemoglobin of 7.2 g/dL (normal for adult women is 12–15) and a ferritin of 3 ng/mL (normal 15–150). The gynaecologist explained gently but clearly that her bleeding was substantially excessive, that the anaemia was a direct result, and that the situation needed both immediate treatment of the anaemia and investigation of the underlying cause.

Priya's story is, sadly, common. The gradual worsening over years, the cultural normalisation that delays help-seeking until anaemia is severe, and the crisis moment — a near-faint, a workplace accident, an incidental finding — that finally triggers presentation are patterns gynaecologists across India recognise. FOGSI awareness campaigns have aimed to reduce this delay by reframing HMB as a medical condition rather than a normal variant, but the cultural shift remains incomplete.

The standard FOGSI evaluation for HMB starts with a structured history, an examination, and a defined set of investigations to identify the cause. Priya's evaluation followed this pathway and shows the steps any woman with HMB should expect.

The history covered her menstrual pattern in detail: cycle length, days of bleeding, estimated blood loss (often scored with the pictorial blood assessment chart, or PBAC, where you record the number and saturation of pads), clots, the timing of changes, and the impact on daily life. Priya scored high on the PBAC, confirming definitely excessive bleeding, and her account of recent worsening fitted a pattern of fibroid growth or adenomyosis.

Family, obstetric and sexual history added context. She had had two normal vaginal deliveries with normal blood loss, no family history of bleeding disorders, used condoms with the rhythm method for Copper IUD vs Hormonal IUD (Mirena): An Indian Guide, and was not pregnant or affected by pelvic infection or prior gynaecological surgery.

Examination included a general assessment (pale, tired, low-normal blood pressure), abdominal examination (a palpable lower-abdominal mass consistent with an enlarged uterus), and pelvic examination (a uterus enlarged to about 12–14 weeks' size, mobile, with multiple firm nodules consistent with Uterine Fibroids in India: Diagnosis and Treatment Options).

The initial blood tests were a complete blood count (confirming severe iron-deficiency anaemia), serum ferritin (severely low at 3 ng/mL), thyroid function (normal), a coagulation screen (normal, ruling out a bleeding disorder), and a urine beta-hCG (negative, ruling out pregnancy). The total cost was around ₹800 at the hospital lab.

Imaging was a transvaginal ultrasound the same day. It showed a substantially enlarged uterus with multiple fibroids (the largest 6 cm in the front wall, plus several smaller ones) and features consistent with Adenomyosis vs Endometriosis: Differences, Diagnosis & Treatment — asymmetrical thickening of the uterine wall with a characteristic junctional zone. The endometrial lining and ovaries were normal. The scan cost ₹1,800 at the attached diagnostic centre.

Further tests were not needed in Priya's case. Where the ultrasound shows an abnormal endometrium (thickening over 12 mm in a premenopausal woman, polyps, or persistent intermenstrual bleeding), an endometrial biopsy is the next step to exclude hyperplasia or cancer — done either as an office Pipelle sample (brief discomfort, around ₹3,000–5,000 with pathology) or as hysteroscopy and curettage under brief anaesthesia (more thorough, around ₹8,000–15,000 privately). For persistent unexplained heavy bleeding, pelvic MRI gives higher-resolution detail, especially for adenomyosis and complex fibroids.

The diagnosis was HMB from a combination of multiple uterine fibroids and adenomyosis — a pairing that accounts for a large share of severe HMB in women in their thirties and forties. The treatment plan had to address three things: the immediate severe anaemia, the ongoing bleeding (so the anaemia could recover), and the underlying structural cause.

The immediate priority was to treat the severe anaemia and start rebuilding Priya's iron stores. The gynaecologist consulted a haematologist and they chose a combined approach. (For the wider picture of why so many Indian women run low, see our guide to iron deficiency in non-pregnant women.)

The first step was an intravenous iron infusion — the fastest way to correct severe iron-deficiency anaemia. Indian options include iron sucrose (several infusions of 200–300 mg a few days apart, around ₹3,000 per infusion) and ferric carboxymaltose (a single 1,000 mg infusion replacing most of the deficit, around ₹8,000–10,000, sold as Ferinject and similar). Priya received one ferric carboxymaltose infusion in the day-care unit — about 30 minutes, well tolerated.

IV iron was followed by oral iron to consolidate recovery and replace ongoing menstrual losses. Current evidence favours alternate-day dosing over daily, which improves absorption with fewer side effects. Priya took ferrous fumarate 300 mg (100 mg elemental iron) every other day, with vitamin C 500 mg to aid absorption — about ₹100 a month for generic ferrous fumarate plus ₹100 for vitamin C.

Dietary support included more iron-rich foods (dark green leafy vegetables, jaggery, dates, spinach, lean meat where eaten, eggs) paired at the same meal with vitamin-C foods (lemon, orange, amla, tomato, capsicum). Tea, coffee and dairy reduce iron absorption, so these were spaced away from meals and iron tablets. As an ovo-lacto-vegetarian, Priya found the dietary side more challenging but achievable with attention to combinations.

A blood transfusion was considered but deferred: Priya was haemodynamically stable and IV iron was expected to work quickly. Transfusion is reserved for haemoglobin below 7 g/dL with symptoms, or for clinically unstable patients — and her response made it unnecessary.

Follow-up haemoglobin rose steadily: from 7.2 at presentation to 9.8 at four weeks (after the infusion), 11.5 at eight weeks, and 12.8 at three months. Ferritin recovered to a healthy 32 ng/mL by three months. The change in energy was dramatic — by six weeks she was no longer breathless on stairs, her hair had stopped thinning, and her fatigue had lifted substantially.

But treating the anaemia did not address the cause. As long as the heavy bleeding continued, iron stores would be depleted again by ongoing losses, and the cycle would repeat. The next phase therefore focused on reducing the bleeding itself.

FOGSI first-line medical therapy for HMB (where there is no contraindicating structural pathology) uses two simple, inexpensive drugs that work through different mechanisms. Priya started both for her next cycle. (Because mefenamic acid also eases cramps, women with painful periods often notice double benefit.)

Mefenamic acid is a non-steroidal anti-inflammatory (NSAID) that inhibits prostaglandin synthesis. Prostaglandins drive both menstrual pain and excessive uterine bleeding, so blocking them reduces both. The standard regimen is 500 mg three times daily, starting one day before the expected period and continuing through the first three to four bleeding days. It is widely available (brands include Meftal and Ponstan, ₹50–100 a month) and reduces menstrual blood loss by about 20–40%. Contraindications include peptic ulcer disease, aspirin-sensitive asthma, chronic kidney disease and anticoagulant use — none applied to Priya.

Tranexamic acid is an antifibrinolytic: it slows the breakdown of clots that form at bleeding sites in the endometrium, reducing total blood loss. The standard regimen is 1,000 mg (1 g) three times daily, starting on the first day of bleeding and continuing for three to five days of heaviest flow. Indian brands include Trapic and Tranlock (₹200–400 a month). It reduces menstrual blood loss by about 40–50% and is generally well tolerated. Contraindications include a history of thromboembolic disease, severe renal impairment, and concurrent use of certain drugs. Because it is taken only on bleeding days, it is more affordable than continuous medication.

The two are commonly combined for additive benefit, working through separate mechanisms (anti-prostaglandin and antifibrinolytic). Priya started both one day before her period and continued through the heaviest days.

Her response was meaningful but partial: blood loss fell by about 40% over two cycles. She now used six to eight pads on the heaviest days rather than twelve to fifteen, passed no clots larger than a small grape, and slept through the night. A real improvement — but the bleeding was still clinically heavy, and her iron stores would keep slowly depleting.

The gynaecologist explained that for structural causes like fibroids and adenomyosis, medical therapy often improves but rarely fully resolves the bleeding. The next step would be more targeted hormonal therapy or a procedure. For many women whose underlying cause is milder than Priya's, first-line therapy alone brings bleeding into a tolerable range; some trial it for 6–12 months and escalate only if the response is inadequate. The choice depends on symptom severity, preference and tolerance for ongoing treatment.

After two more cycles of mefenamic acid plus tranexamic acid with continued heavy bleeding, Priya and her gynaecologist discussed adding the levonorgestrel-releasing intrauterine system (LNG-IUS, best known as Mirena). This is the most effective non-surgical treatment for HMB and is increasingly first-line in international guidelines, including NICE.

The LNG-IUS is a small T-shaped device placed in the uterus that slowly releases the progestin levonorgestrel directly into the cavity. The local progesterone effect thins the endometrium over the first months, dramatically reducing blood loss. Studies show it cuts menstrual blood loss by 80–95% over six months, and many women become essentially period-free after the first year. It also provides effective long-acting reversible contraception for five to seven years and protects the endometrium from hyperplasia.

In India, Mirena is available through major hospital chains and gynaecology clinics, costing roughly ₹15,000–22,000 including insertion. Insertion is an office procedure, usually without anaesthesia (some women request local anaesthesia or mild oral sedation), taking ten to fifteen minutes. There is moderate cramping during and after insertion, managed with NSAIDs. Amortised over five to seven years, the cost is a few thousand rupees a year — cost-effective against ongoing medication.

The early months can be discouraging. Many women have irregular spotting and unpredictable bleeding for three to six months as the endometrium adapts, and this is why some discontinue before reaching the benefit phase. Counselling about this expected settling-in period matters: the pattern typically stabilises by month six and becomes much lighter than before.

Priya's Mirena was inserted in the clinic — uncomfortable but manageable with pre-dosed NSAIDs, and she returned to work the next day. The first three months ran exactly as predicted: irregular, lighter-than-before but more frequent bleeding. By month four the pattern began to settle, and by month six she had very light periods of two to three days, like her teenage years before the gradual worsening began.

At six months her haemoglobin (13.2 g/dL) and ferritin (68 ng/mL) were comfortably normal, and oral iron was reduced to maintenance and then stopped. The quality-of-life gain was substantial — no longer planning life around periods, no workplace anxiety, sleeping through bleeding days.

The LNG-IUS is especially well-suited to HMB from Adenomyosis Treatment in India: Mirena, UAE, Ablation, Hysterectomy, a major part of Priya's pathology; the local progesterone effect specifically benefits adenomyotic tissue. For primarily fibroid-driven HMB the response is also good but a little less consistent, particularly with large submucosal fibroids that distort the cavity and affect placement.

For Priya, light-but-persistent residual bleeding plus pressure symptoms from her large fibroids (urinary frequency, pelvic heaviness) meant the conversation about more definitive surgery stayed open — but with the time and quality of life the Mirena had bought her, she could approach that decision calmly.

For women whose HMB does not respond adequately to medical management, or who have structural pathology medication cannot fully address, surgery offers more definitive resolution. The FOGSI framework emphasises shared decision-making, weighing the cause, the woman's age, her reproductive plans, her preferences and the available expertise.

Endometrial ablation is a minimally invasive procedure that destroys the uterine lining (by thermal balloon, hydrothermal, radiofrequency, microwave or cryotherapy). It suits women with HMB from a relatively normal-sized uterus who have completed their family and want to avoid hysterectomy. Done as a day case under brief general or regional anaesthesia (30–60 minutes), it produces amenorrhoea or much-reduced periods in 70–90% of women within six months. Contraindications include a desire for future pregnancy (it is not contraception, and pregnancy after ablation carries significant complications), undiagnosed bleeding (endometrial pathology must be excluded first), cavity-distorting submucosal fibroids and a substantially enlarged uterus. Cost is roughly ₹50,000–1,00,000 privately, with recovery in a few days. In Priya's case her fibroid size and adenomyosis made ablation a suboptimal choice.

Myomectomy removes fibroids while preserving the uterus — the option for women who want to keep fertility and have symptomatic fibroids. The approach depends on the fibroids. Hysteroscopic myomectomy (through the cervix) suits submucosal fibroids protruding into the cavity, is a day case (around ₹40,000–80,000), and recovers fast. Laparoscopic myomectomy (keyhole abdominal) suits moderate intramural and subserosal fibroids, needs one to two days in hospital (around ₹80,000–1,50,000) with two to three weeks' recovery. Open abdominal myomectomy is for very large or numerous fibroids, needs three to four days in hospital (around ₹1,00,000–2,00,000) with four to six weeks' recovery. Recurrence is significant (20–40% over five years), especially in younger women, but the uterus — and the possibility of future pregnancy — is preserved.

Uterine artery embolisation is a minimally invasive radiological procedure by an interventional radiologist that blocks the fibroids' blood supply so they shrink over months. It suits women with symptomatic fibroids who want to avoid major surgery. Done under conscious sedation with one to two days in hospital (around ₹1,00,000–2,00,000) and two to four weeks' recovery, it can affect fertility and ovarian function and is usually reserved for women who have completed their family or who prefer it despite this. It is available at major metropolitan hospitals with interventional radiology.

Hysterectomy is the definitive treatment for HMB from significant structural pathology in women who have completed their family and exhausted less invasive options. It removes the uterus and ends menstruation entirely. The modern approach is laparoscopic, vaginal or robotic hysterectomy rather than open where feasible. Laparoscopic hysterectomy needs two to three days in hospital (around ₹1,50,000–3,00,000 privately) with two to four weeks' recovery. Vaginal hysterectomy is done entirely through the vagina without abdominal incisions, with similar cost and among the fastest recovery. Open abdominal hysterectomy is used for very large uteri or complex pathology, needing three to five days in hospital (around ₹80,000–2,00,000) with six to eight weeks' recovery. Whether to remove the ovaries at the same time depends on age, cancer risk and preference; ovaries are usually retained in women under 45 to preserve hormonal and cardiovascular health.

After extensive discussion, Priya chose to continue with the Mirena — which was giving substantial benefit — and to defer surgery, monitoring her symptoms over the next year or two and reconsidering hysterectomy if things worsened. For many women in this situation the Mirena buys enough time that surgery is deferred until perimenopause, when falling estrogen often shrinks fibroids and adenomyosis becomes less symptomatic — at which point surgery may no longer be needed.

Surgical decision-making for HMB is highly individualised; the right choice for one woman is not the right choice for another. FOGSI emphasises that the woman is the decision-maker and the gynaecologist's role is to give accurate information, support her through the decision and perform the chosen intervention skilfully. The shift from older paternalistic practice to shared decision-making is one of the important changes in Indian gynaecology over the past two decades.

• Soaking through a sanitary pad or tampon every hour for two or more hours in a row
• Passing clots larger than a ₹2 coin (about 25 mm)
• Bleeding that lasts longer than seven days
• Having to get up to change pads through the night
• Any fainting or near-fainting that may be related to bleeding
• Feeling exhausted out of proportion to your activity, or breathless on minor exertion
• Hair thinning or other signs of nutritional deficiency
• Bleeding through your clothes in public despite using protection
• Bleeding between periods, after sex, or any bleeding after menopause

Priya's story shows one of the persistent patterns in Indian women's health: the cultural normalisation of heavy bleeding that delays care. Indian studies have documented that women with HMB typically present after years of progressive worsening, with anaemia often already advanced. The pattern crosses socioeconomic lines — lower-income women may delay through limited access, higher-income women through the habit of treating menstrual difficulty as normal and not worth medical attention.

Several specific factors contribute. Menstrual silence in many families means women rarely compare their bleeding with others and cannot calibrate what is normal. The cultural acceptance of female suffering means complaints are sometimes met with dismissal rather than concern. The association of menstruation with ritual impurity in some communities creates discomfort around even private discussion. Lower meat intake combined with limited dietary iron raises the baseline of iron deficiency that compounds any blood loss. And limited gynaecological access in many rural and small-town settings means women may have no regular doctor to consult.

FOGSI awareness campaigns have aimed to address this by promoting the message that heavy menstrual bleeding is treatable and should be treated. Digital health platforms — telemedicine and reproductive-health apps — have made information more accessible, particularly in smaller cities and rural areas.

If you recognise yourself or someone you know in Priya's story, the practical advice is to seek evaluation without waiting (see the red flags above). The cost is modest: a private gynaecology consultation runs ₹500–2,000, basic blood tests ₹500–800, and a transvaginal ultrasound ₹1,000–2,500 — a total of ₹3,000–5,000 for the diagnostic foundation. At government hospitals and primary health centres the same evaluation is free or minimal. The investment is small against years of suffering and the long-term health impact of untreated HMB.

The family conversation matters too. Daughters who watch their mothers and aunts struggle silently learn to expect the same; mothers who talk openly about menstrual health and model seeking care transmit a healthier pattern. The intergenerational change is slow but real.

Workplaces are shifting as well. Some Indian companies have introduced menstrual leave policies (typically one paid day a month), and managers who openly support their teams model a different culture from the older norm of silence and stoicism. For the related conditions behind heavy and painful cycles, see our guides to perimenopause cramps and what endometriosis is.

Two years on from her presentation with severe anaemia, Priya's life has transformed in ways she did not anticipate. The Mirena continues to control her bleeding — very light periods of two to three days each cycle, like her teenage years. Her haemoglobin has stayed comfortably normal without ongoing iron supplements, and her energy is back to her late twenties.

The broader changes have been emotional and relational as much as physical. She had not realised how much mental energy the anxiety about leaks, the workplace embarrassment and the chronic fatigue had consumed until those concerns lifted. Her productivity at work improved noticeably; she had been operating below capacity for years. Her relationship with her husband improved as she became more available emotionally and physically, and she had more patience with her children. She started exercising again — yoga twice a week and evening walks — which further improved her energy and mood.

Her perspective on the years before help shifted with the contrast. She now talks about it as an example of how Indian women are conditioned to normalise suffering, and how important it is to recognise that medical help exists for problems we are taught to bear silently. She has become a voice in her friend group, encouraging others to seek evaluation. Three friends have since been assessed for symptoms they had ignored — one diagnosed with substantial fibroids causing her own anaemia.

The fibroid follow-up has been stable. Yearly ultrasounds show no further growth, and one smaller fibroid has shrunk slightly — the expected pattern as she nears her early forties. The Mirena continues to perform well and may be replaced after its seven-year span. As she approaches perimenopause, her fibroids will likely shrink further with declining estrogen, and she may eventually need no further treatment.

The lessons Priya shares: heavy menstrual bleeding is a medical condition, not something to bear silently. Evaluation by a gynaecologist is straightforward and affordable. The treatment options are good and well tolerated. The quality-of-life improvement from successful treatment is substantial and often surprising. The cultural conditioning that makes women endure menstrual symptoms is not in their interest and should be actively resisted. And the other women in your life need encouragement to seek the same care.

Her story also shows that HMB management is usually step-by-step rather than a single intervention. Many women do well on first-line medication alone; others add the Mirena; a smaller group needs a procedure. Matching treatment intensity to the individual is the gynaecologist's craft — FOGSI provides the structure, but the application is individualised.

The public-health implication is large: HMB is a major contributor to iron-deficiency anaemia in Indian women, which has profound consequences for productivity, wellbeing and family welfare. National Family Health Survey rounds have repeatedly documented iron-deficiency anaemia in over half of Indian women. While the causes are multiple — dietary intake, malabsorption, infection — untreated HMB is a substantial driver in premenopausal adults, and identifying and treating it at population scale would meaningfully reduce the burden of anaemia and its consequences.

• NICE Guideline NG88: Heavy menstrual bleeding — assessment and management
• ACOG: Heavy Menstrual Bleeding (FAQ and clinical guidance)
• WHO: Anaemia (fact sheet and prevalence data)
• Ministry of Health and Family Welfare, India: National Family Health Survey (NFHS-5) — anaemia among women
• Anemia Mukt Bharat (National Iron Plus Initiative), MoHFW Government of India